Subject: Request for Collaboration on Tax Implications in Upcoming Publication

---

From: Raymond Mayo <gwendolynklein@example.net>  
To: Martin Mckinney <friedmantamara@example.net>  
Date: October 5, 2023, 9:15 AM  

Hi Martin,

I hope this message finds you well. I'm reaching out to discuss the upcoming publication on "Innovations in Oncology Treatments" scheduled for release next quarter. As you know, tax implications play a crucial role in how we position our products to stakeholders and investors.

Could we schedule a time to discuss integrating a section on tax strategies and compliance into the publication? I believe it will add significant value, particularly around R&D tax credits and international tax considerations.

Are you available for a brief meeting this week? I’m open on Thursday afternoon from 2 PM to 4 PM. Let me know if that works for you or suggest an alternative time. You can also reach me at my direct line at (908) 555-0145 if that's easier.

Looking forward to your thoughts.

Best regards,

Raymond Mayo  
Tax Adviser  
Merck & Co., Inc.

---

From: Martin Mckinney <friedmantamara@example.net>  
To: Raymond Mayo <gwendolynklein@example.net>  
Date: October 5, 2023, 1:30 PM  

Hi Raymond,

Thanks for reaching out! I completely agree that including a section on tax strategies is vital for our audience, especially given the complex landscape of pharmaceutical taxation.

Thursday afternoon works perfectly for me—let's plan to meet at 2:30 PM. We can use conference room B on the 9th floor; it should be free at that time. I'll bring the draft content along with some initial thoughts on how we can structure this section.

Looking forward to our discussion. If anything changes, feel free to shoot me an email or call my cell at (908) 555-0198.

Best,  
Martin Mckinney  
Publishing Copy  
Merck & Co., Inc.  